Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Total Liabilities (2023 - 2025)

Historic Total Liabilities for Connect Biopharma Holdings (CNTB) over the last 3 years, with Q3 2025 value amounting to $12.0 million.

  • Connect Biopharma Holdings' Total Liabilities changed N/A to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year change of. This contributed to the annual value of $9.1 million for FY2024, which is 6476.54% down from last year.
  • Connect Biopharma Holdings' Total Liabilities amounted to $12.0 million in Q3 2025.
  • In the past 5 years, Connect Biopharma Holdings' Total Liabilities registered a high of $25.9 million during Q4 2023, and its lowest value of $9.1 million during Q4 2024.
  • Its 3-year average for Total Liabilities is $13.4 million, with a median of $11.4 million in 2025.
  • Its Total Liabilities has fluctuated over the past 5 years, first plummeted by 6476.54% in 2024, then skyrocketed by 1280.35% in 2025.
  • Connect Biopharma Holdings' Total Liabilities (Quarter) stood at $25.9 million in 2023, then crashed by 64.77% to $9.1 million in 2024, then soared by 31.5% to $12.0 million in 2025.
  • Its Total Liabilities was $12.0 million in Q3 2025, compared to $11.4 million in Q2 2025 and $9.8 million in Q1 2025.